Seqirus announced it has begun shipping seasonal influenza vaccines for the upcoming 2017/18 flu season.

Seqirus will be offering both trivalent and quadrivalent formulations of the influenza vaccine, which were developed using egg- and cell-based technologies. In addition, Fluad™ (influenza vaccine, adjuvanted) will be available for patients aged ≥65 years, as well as Flucelvax Quadrivalent® (influenza vaccine) for patients aged ≥4 years.

Specific vaccines in the Seqirus portfolio for the upcoming flu season include Afluria Quadrivalent® (ages ≥18 years), the egg-based quadrivalent influenza vaccine, and Afluria® (ages ≥5 years) and Fluvirin® (ages ≥4 years), the egg-based trivalent influenza vaccines. 

Rapivab® (peramivir injection) is also available as a 1-dose intravenous (IV) antiviral treatment for acute influenza in patients aged ≥18 years.

Seqirus vaccines are supplied as prefilled syringes as well as multi-dose vials. A needle-free injection option is also provided for Afluria and Afluria Quadrivalent.

Related Articles

Reference

Seqirus begins shipping 2017-2018 influenza vaccines to the U.S. market [news release]. Summit, NJ: Seqirus Inc. http://www.seqirus.com/newsroom/Seqirus-Begins-Shipping-2017-2018-Influenza-Vaccines-to-the-US-Market. Published July 20, 2017. Accessed August 17, 2017. 

This article originally appeared on MPR